BioMarin Pharmaceutical (BMRN) ROE - Return on Equity

Current and historical Return on Equity (ROE) values for BioMarin Pharmaceutical (BMRN) over the last 10 years.

Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $16.890B $1.314B
BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.